On Tuesday, Kymera Therapeutics shares leaped 12% following the biotechnology firm's update on its product pipeline. The New York-based company announced progress in its programs for atopic dermatitis ...
Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate ...
Groundbreaking therapies for inflammatory diseases, ambitious clinical milestones, and a cash-rich balance sheet fuel investor confidence.
Kymera Therapeutics (KYMR) stock surged as the company outlined its 2025 outlook at the J.P. Morgan Healthcare Conference. Read more here.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...